Effect of chain length and branching on the in vitro metabolism of a series of parabens in human liver S9, human skin S9, and human plasma

被引:12
|
作者
Obringer, Cindy [1 ]
Wu, Shengde [1 ]
Troutman, John [1 ]
Karb, Michael [1 ]
Lester, Cathy [1 ]
机构
[1] Procter & Gamble Co, 8700 Mason Montgomery Rd Mason, Cincinnati, OH 45040 USA
关键词
Parabens; Ester metabolism; Carboxylesterase; Liver; Skin; Plasma; Clearance; CARBOXYLESTERASE ISOZYMES; DRUG-METABOLISM; HYDROLYSIS; ESTERS; METHYL; MICROSOMES; PROPYL; URINE; BUTYL; RAT;
D O I
10.1016/j.yrtph.2021.104918
中图分类号
DF [法律]; D9 [法律]; R [医药、卫生];
学科分类号
0301 ; 10 ;
摘要
Parabens are antimicrobial compounds used as preservatives in cosmetics, foods, and pharmaceuticals. Paraben exposure occurs through a variety of routes including dermal absorption, ingestion, and inhalation. Ester bond hydrolysis has been shown to be the predominant biotransformation for this chemical class. Here we evaluated a series of parabens of increasing alkyl chain length and branching in addition to the aryl side chain of phenyl paraben (PhP). We evaluated the parabens under full Michaelis-Menten (MM) parameters to obtain intrinsic clearance values and found different trends between human liver and skin, which correlate with the predominant esterase enzymes in those matrices, respectively. In liver, where carboxylesterase 1 (CES1) is the predominant esterase enzyme, the shorter chain parabens were more readily metabolized, while in skin, where carboxylesterase 2 (CES2) is the predominant esterase enzyme, the longer chain parabens were more readily metabolized. Alkyl chain branching reduced the hydrolysis rates relative to those for the straight chain compounds, while the addition of a phenyl group, as in PhP, showed an increase in hydrolysis, producing the highest observed hydrolysis rate for skin. These data summarize the structure-metabolism relationship for a series of parabens and contribute to the safety assessment of this class of compounds.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Metabolic characteristics of Tanshinone I in human liver microsomes and S9 subcellular fractions
    Li, Yue
    Fan, Yujuan
    Su, Huizong
    Wang, Qian
    Li, Guo-Fu
    Hu, Yiyang
    Jiang, Jian
    Tan, Bo
    Qiu, Furong
    XENOBIOTICA, 2019, 49 (02) : 152 - 160
  • [22] In vitro metabolism of etoperidone in rat hepatic S9 fraction
    McKown, LA
    Wu, WN
    FASEB JOURNAL, 1996, 10 (03): : 1014 - 1014
  • [23] An in vitro reporter gene assay method incorporating metabolic activation with human and rat S9 or liver microsomes
    Sumida, K
    Ooe, N
    Nagahori, H
    Saito, K
    Isobe, N
    Kaneko, H
    Nakatsuka, I
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 280 (01) : 85 - 91
  • [24] IN VITRO BIOTRANSFORMATION RATES IN FISH LIVER S9: EFFECT OF DOSING TECHNIQUES
    Lee, Yung-Shan
    Lee, Danny H. Y.
    Delafoulhouze, Maximilien
    Otton, S. Victoria
    Moore, Margo M.
    Kennedy, Chris J.
    Gobas, Frank A. P. C.
    ENVIRONMENTAL TOXICOLOGY AND CHEMISTRY, 2014, 33 (08) : 1885 - 1893
  • [25] EFFECTS OF HUMAN PLACENTAL S9 AND INDUCED RAT-LIVER S9 ON THE MUTAGENICITY OF DRINKING WATERS PROCESSED FROM HUMUS-RICH SURFACE WATERS
    VARTIAINEN, T
    LAMPELO, S
    ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 1990, 15 (04) : 198 - 204
  • [26] Dataset from proteomic analysis of rat, mouse, and human liver microsomes and S9 fractions
    Golizeh, Makan
    Schneider, Christina
    Ohlund, Leanne B.
    Sleno, Lekha
    DATA IN BRIEF, 2015, 3 : 95 - 98
  • [27] In vitro biotransformation of the bradykinin antagonist, RWJ-414814, in rat and human hepatic and human pulmonary S9 fractions
    Wu, WN
    McKown, LA
    Youngman, MA
    Carson, JR
    Dax, SL
    Jetter, M
    DRUG METABOLISM REVIEWS, 2002, 34 : 81 - 81
  • [28] Hepatic in vitro metabolism of peptides; Comparison of human liver S9, hepatocytes and Upcyte hepatocytes with cyclosporine A, leuprorelin, desmopressin and cetrorelix as model compounds
    Jyrkas, Juha
    Tolonen, Ari
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2021, 196
  • [29] Micronucleous test modification using the human fraction S9 for metabolic activation
    Arnobio, A.
    Moreno, S. R. F.
    Olej, B.
    Cardoso, G. P.
    Caldas, L. Q. A.
    TOXICOLOGY LETTERS, 2011, 205 : S173 - S173
  • [30] In vitro metabolism of a potent HIV-protease inhibitor (141W94) using rat, monkey and human liver S9
    Singh, R
    Chang, SY
    Taylor, LCE
    RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 1996, 10 (09) : 1019 - 1026